Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Mathematical Modeling: Problem Solving01:29

Mathematical Modeling: Problem Solving

475
Mathematical modeling transforms real-world scenarios into mathematical expressions, allowing for structured problem-solving and analysis. This process involves defining the situation, assigning variables to measurable quantities, selecting an appropriate model, and solving the resulting equation. Such models are invaluable in finance, providing precise methods to evaluate investments, loans, and repayment structures.A widely used example is the calculation of fixed monthly payments on a loan,...
475
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal control for anti-abeta treatment in Alzheimer's disease using a reaction-diffusion model.

Journal of the Royal Society, Interface·2026
Same author

PDE and agent based simulation approaches to Ischemic Dermal Wound Closure.

PloS one·2026
Same author

Learning patient-specific spatial biomarker dynamics via operator learning for Alzheimer's disease progression.

NPJ systems biology and applications·2026
Same author

Optimal error estimates of the diffuse domain method for second order parabolic equations.

BIT. Numerical mathematics·2026
Same author

Unveiling Scaling Laws of Parameter Identifiability and Uncertainty Quantification in Data-Driven Biological Modeling.

ArXiv·2026
Same author

ZENN: A thermodynamics-inspired computational framework for heterogeneous data-driven modeling.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Mar 11, 2026

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.8K

Mathematical model on Alzheimer's disease.

Wenrui Hao1, Avner Friedman2

  • 1Department of Mathematics, The Penn State University, University Park, 16802, PA, USA. hao.50@mbi.osu.edu.

BMC Systems Biology
|November 20, 2016
PubMed
Summary

A new mathematical model simulates Alzheimer's disease (AD) progression. Combined therapy with TNF-α inhibitors and anti-amyloid-beta drugs shows potential for slowing AD.

Keywords:
Alzheimer diseaseDrug treatmentMathematical modeling

More Related Videos

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

1.3K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.8K

Related Experiment Videos

Last Updated: Mar 11, 2026

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.8K
Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

1.3K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.8K

Area of Science:

  • Neuroscience
  • Computational Biology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder impacting memory and cognition.
  • AD is characterized by amyloid-beta plaques and hyperphosphorylated tau tangles.
  • Current treatments cannot cure, halt, or slow AD progression, with significant future healthcare cost implications.

Purpose of the Study:

  • To develop a comprehensive mathematical model of Alzheimer's disease.
  • To simulate the effects of various drug therapies on AD progression using the model.

Main Methods:

  • A system of partial differential equations was developed to model AD.
  • The model incorporates neurons, astrocytes, microglia, peripheral macrophages, amyloid-beta aggregation, and hyperphosphorylated tau.

Main Results:

  • Simulations were performed to evaluate drug efficacy.
  • The model allowed for the testing of drugs that have failed or are in clinical trials.

Conclusions:

  • Combined therapy with TNF-α inhibitors and anti-amyloid-beta agents may significantly slow AD progression.
  • Mathematical modeling offers a promising approach to test therapeutic strategies for Alzheimer's disease.